Adolescents with childhood-onset GHD: How do we get them to peak bone mass?

Hormone Research

Volumn 65, Issue SUPPL. 2, 2006, Pages 17-22

  Shalet, Stephen ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Adolescents; Bone mass; Growth hormone deficiency; Growth hormone treatment; Transition

Indexed keywords

GROWTH HORMONE; HUMAN GROWTH HORMONE;

BODY HEIGHT; BONE DENSITY; BONE MASS; BONE STRENGTH; CLINICAL TRIAL; CONFERENCE PAPER; DEVELOPMENT; DOSE RESPONSE; DRUG EFFICACY; FRAGILITY FRACTURE; GROWTH HORMONE DEFICIENCY; GROWTH RATE; HORMONE RESPONSE; HORMONE SUBSTITUTION; HUMAN; ONSET AGE; OSTEOPOROSIS; PHYSICAL DEVELOPMENT; PRIORITY JOURNAL; PUBERTY; QUALITY OF LIFE; STATISTICAL SIGNIFICANCE; ADOLESCENT; PHYSIOLOGY; REVIEW;

ADOLESCENT; BODY HEIGHT; BONE DENSITY; HUMAN GROWTH HORMONE; HUMANS;

EID: 33746457499     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091750     Document Type: Conference Paper

References (27)

1. Bonjour JP, Theintz G, Buchs B, Slosman D, Rizzoli R: Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab 1991;73:555-563.
2. Matkovic V, Jelic T, Wardlaw GM, Ilich JZ, Goel PK, Wright JK, Andon MB, Smith KT, Heaney RP: Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis. Inference from a cross-sectional model. J Clin Invest 1994;93:799-808.
3. Drake WM, Howell SJ, Monson JP, Shalet SM: Optimizing GH therapy in adults and children. Endocr Rev 2001;22:425-450.
4. Kassem M, Mosekilde L, Eriksen EF: Growth hormone stimulates proliferation of normal human bone marrow stromal osteoblast precursor cells in vitro. Growth Regul 1994;4:131-135.
5. Brixen K, Nielsen HK, Mosekilde L, Flyvbjerg A: A short course of recombinant human growth hormone treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers. J Bone Miner Res 1990;5:609-618.
6. Hansen TB, Brixen K, Vahl N, Jorgensen JO, Christiansen JS, Mosekilde L, Hagen C: Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study. J Clin Endocrinol Metab 1996;81:3352-3359.
7. Baroncelli GI, Bertelloni S, Ceccarelli C, Cupelli D, Saggese G: Dynamics of bone turnover in children with GH deficiency treated with GH until final height. Eur J Endocrinol 2000;142:549-556.
8. de Boer H, Blok GJ, van Lingen A, Teule GJ, Lips P, van der Veen EA: Consequences of childhood-onset growth hormone deficiency for adult bone mass. J Bone Miner Res 1994;9:1319-1326.
9. O'Halloran DJ, Tsatsoulis A, Whitehouse RW, Holmes SJ, Adams JE, Shalet SM: Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency. J Clin Endocrinol Metab 1993;76:1344-1348.
10. Sartorio A, Ortolani S, Conti A, Cherubini R, Galbiati E, Faglia G: Effects of recombinant growth hormone (GH) treatment on bone mineral density and body composition in adults with childhood onset growth hormone deficiency. J Endocrinol Invest 1996;19:524-529.
11. Johansson AG, Burman P, Westermark K, Ljunghall S: The bone mineral density in acquired growth hormone deficiency correlates with circulating levels of insulin-like growth factor I. J Intern Med 1992;232:447-452.
12. Attanasio AF, Howell S, Bates PC, Frewer P, Chipman J, Blum WF, Shalet SM: Body composition, IGF-I and IGFBP-3 concentrations as outcome measures in severely GH-deficient (GHD) patients after childhood GH treatment: a comparison with adult onset GHD patients. J Clin Endocrinol Metab 2002;87:3368-3372.
13. Bouillon R, Koledova O, Bezlepkina O, Nijs J, Shavrikhova E, Nagaeva E, Chikulaeva O, Peterkova V, Dedov I, Bakulin A, Oganov V, Attanasio AF: Bone status and fracture prevalence in Russian adults with childhood-onset growth hormone deficiency. J Clin Endocrinol Metab 2004;89:4993-4998.
14. Holmes SJ, Economou G, Whitehouse RW, Adams JE, Shalet SM: Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 1994;78:669-674.
15. Kaufman JM, Taelman P, Vermeulen A, Vandeweghe M: Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset. J Clin Endocrinol Metab 1992;74:118-123.
16. Rosen T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G, Bengtsson BA: Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol 1997;137:240-245.
17. Murray RD, Columb B, Adams JE, Shalet SM: Low bone mass is an infrequent feature of the adult growth hormone deficiency syndrome in middle-age adults and the elderly. J Clin Endocrinol Metab 2004;89:1124-1130.
18. Janssen YJ, Hamdy NA, Frolich M, Roelfsema F: Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1998;83:2143-2148.
19. Toogood AA, Adams JE, O'Neill PA, Shalet SM: Elderly patients with adult-onset growth hormone deficiency are not osteopenic. J Clin Endocrinol Metab 1997;82:1462-1466.
20. Guyda HJ: Four decades of growth hormone therapy for short children: what have we achieved? J Clin Endocrinol Metab 1999;84:4307-4316.
21. Ranke MB, Price DA, Albertsson-Wikland K, Maes M, Lindberg A: Factors determining pubertal growth and final height in growth hormone treatment of idiopathic growth hormone deficiency. Horm Res 1997;48:62-71.
22. Drake WM, Carroll PV, Maher KT, Metcalfe KA, Camacho-Hubner C, Shaw NJ, Dunger DB, Cheetham TD, Savage MO, Monson JP: The effect of cessation of growth hormone (GH) therapy on bone mineral accretion in GH-deficient adolescents at the completion of linear growth. J Clin Endocrinol Metab 2003;88:1658-1663.
23. Underwood LE, Attie KM, Baptista J; Genentech Collaborative Study Group: Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study. J Clin Endocrinol Metab 2003;88:5273-5280.
24. Shalet SM, Shavrikova E, Cromer M, Child CJ, Keller E, Zapletalova J, Moshang T, Blum WF, Chipman JJ, Quigley CA, Attanasio AF: Effect of growth hormone (GH) treatment on bone in postpubertal GH-deficient patients: a 2-year randomized, controlled, dose-ranging study. J Clin Endocrinol Metab 2003;88:4124-4129.
25. Mauras N, Pescovitz OH, Allada V, Messig M, Wajnrajch MP, Lippe B; Transition Study Group: Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial. J Clin Endocrinol Metab 2005;90:3946-3955.
26. Kanis JA: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994;4:368-381.
27. Clayton PE, Cuneo RC, Juul A, Monson JP, Shalet SM, Tauber M; European Society of Paediatric Endocrinology: Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol 2005;152:165-170.